Cipla

Pharmaceutical firm Cipla Ltd on Friday said it is voluntarily recalling six batches of Albuterol Sulfate inhalation aerosol in the US market due to container defect.

The recent decline in the stock market has unnerved investors and traders alike. But pharma stocks are rising. Find out why and other implications.

Pharma stocks are in focus amid renewed fears of Covid outbreaks and have rallied between 5-15% in the past couple of days.

Pharmaceutical firm Cipla has announced a 10.9 per cent growth in its profit after tax to Rs 789 crore for the quarter ended September 2022, against Rs 711 crore in the year-ago period.

Leading drug firms Dr Reddy's Laboratories, Cipla and Aurobindo Pharma are recalling different products in the US market for various issues, according to the US Food and Drug Administration.

The domestic stock indices are likely to trade lower on Tuesday, taking cues from their global peers.

The domestic stock indices are likely to trade lower on Monday, taking cues from the global markets.

As economic realities of high inflation and slowing growth set in, the BSE Sensex dropped more than 10% since its January 2022 peak

The Indian equity indices on Friday traded lower led by selling pressure in information technology and pharma stocks during opening deals.

Drug major Cipla on Wednesday said that Naina Lal Kidwai has resigned as independent director on its board, with effect from March 31, 2022

Cipla on Tuesday reported a 2.6 per cent decline in its consolidated profit after tax to Rs 729 crore for the third quarter ended on December 31, 2021

Pharma Stocks Today: Pharmaceutical shares such as Cipla, Dr Reddy's Laboratories, Torrent Pharma, Sun Pharma Industries gained around two per cent each on Wednesday

The Indian equity benchmarks turned positive in a highly volatile trade on Monday led by gains in IT and pharma stocks.

The domestic stock markets are expected to trade cautiously on Wednesday, taking cues from the global markets.

The company's EBITDA or earnings before interest, tax, depreciation and amortisation also went up by 4.2 per cent to Rs 1,226.2 crore

Pharmaceutical firm Cipla Ltd on Friday said it is voluntarily recalling six batches of Albuterol Sulfate inhalation aerosol in the US market due to container defect.

The recent decline in the stock market has unnerved investors and traders alike. But pharma stocks are rising. Find out why and other implications.

Pharma stocks are in focus amid renewed fears of Covid outbreaks and have rallied between 5-15% in the past couple of days.

Pharmaceutical firm Cipla has announced a 10.9 per cent growth in its profit after tax to Rs 789 crore for the quarter ended September 2022, against Rs 711 crore in the year-ago period.

Leading drug firms Dr Reddy's Laboratories, Cipla and Aurobindo Pharma are recalling different products in the US market for various issues, according to the US Food and Drug Administration.

The domestic stock indices are likely to trade lower on Tuesday, taking cues from their global peers.

The domestic stock indices are likely to trade lower on Monday, taking cues from the global markets.

As economic realities of high inflation and slowing growth set in, the BSE Sensex dropped more than 10% since its January 2022 peak

The Indian equity indices on Friday traded lower led by selling pressure in information technology and pharma stocks during opening deals.

Drug major Cipla on Wednesday said that Naina Lal Kidwai has resigned as independent director on its board, with effect from March 31, 2022

Cipla on Tuesday reported a 2.6 per cent decline in its consolidated profit after tax to Rs 729 crore for the third quarter ended on December 31, 2021

Pharma Stocks Today: Pharmaceutical shares such as Cipla, Dr Reddy's Laboratories, Torrent Pharma, Sun Pharma Industries gained around two per cent each on Wednesday

The Indian equity benchmarks turned positive in a highly volatile trade on Monday led by gains in IT and pharma stocks.

The domestic stock markets are expected to trade cautiously on Wednesday, taking cues from the global markets.

The company's EBITDA or earnings before interest, tax, depreciation and amortisation also went up by 4.2 per cent to Rs 1,226.2 crore